OVERALL PROGRAMME REVIEW

GLOBAL STRATEGY AND PLAN OF ACTION ON PUBLIC HEALTH, INNOVATION AND INTELLECTUAL PROPERTY (GSPA-PHI)

OPEN SESSION
GSPA-PHI Background

• The GSPA-PHI has been developed through an inter-governmental working group and endorsed at the 61st WHA in 2008 - (WHA 61.12).
• The aim of the GSPA-PHI is to promote new thinking on innovation and access to medicines.
• and to secure an enhanced and sustainable basis/framework for needs-driven essential health research and development, relevant to diseases that disproportionately affect developing countries.
• GSPA-PHI timeframe has been extended to 2022.
GSPA-PHI: 8 Elements

1- Prioritizing research & development needs
2- Promoting research and development
3- Building and improving innovative capacity
4- Transfer of technology
5- Application and management of IP to contribute to innovation and promote Public Health
6- Improving delivery and access
7- Promoting sustainable financing mechanisms
8- Establishing monitoring and reporting systems
GSPA – PHI Evaluation and Review

- WHA 68.18, requested WHO DG to initiate a comprehensive evaluation of the implementation of GSPA-PHI - documenting achievements, challenges, recommendations for addressing gaps – Evaluation was presented at 70th WHA

- Member States requested WHO DG to carry out an overall programme review (WHA68.18) - the mission of the Review is to look forward, in the current broad policy context and recommend improved policies and actions for the next stages of GSPA-PHI

- A panel was established with 18 experts with diverse and complementary expertise covering the 8 elements of the GSPA-PHI, taking into account gender balance and equal regional representation; endorsed by 140th EB Officers, in January 2017
Terms of reference of the Review

• (a) assess the continued relevance of the aim and objectives and the eight elements of the GSPA-PHI;
• (b) consider the evaluation of the implementation so far and its key barriers;
• (c) review achievements, good practices, success factors, opportunities, gaps, weaknesses, unsuccessful efforts, remaining challenges, and value for money;
• (d) invite appropriate input and comment from WIPO, WTO, and UNCTAD and other relevant intergovernmental organizations;
• (e) recommend a way forward, including elements/actions to be added, enhanced or concluded in the implementation until 2022
• (f) submit a final report to the Health Assembly in 2018, including the assessment of the GSPA-PHI and recommendations on the way forward
Proposed Method of Work

- Face to face meetings of the Review panel held in March, June and September at WHO headquarters.
- A half-day open session organized at each panel meeting to allow input from Member States, United Nations specialized agencies and all categories of non-State actors in line with FENSA.
- The GSPA-PHI Review secretariat will make all necessary arrangements to ensure that the review is conducted at “arm’s length” and with full attention to avoid conflicts of interests.
- The review shall be carried out in accordance with principles such as:
  - independence,
  - impartiality,
  - inclusiveness, and
  - transparency.
Proposed Method of work

• Additional information will be gathered from Member States and stakeholders through web based questionnaires and phone or face to face interviews.
• Input will also be sought from WHO Regional Offices and other regional institutions and communities.
• Other evidence in the form of reports or peer reviewed publications will also be used to inform the review.
• The panel will commission extra research, through the GSPA-PHI secretariat, on specific subjects.
Review of progress

- First review panel meeting, 23 and 24 March 2017 to define its method of work, identify deliverables and timelines, as well as the structure of the review report.
- 3 sub-groups established and outlines of first 3 chapters drafted
  Chapter 1: Setting the scene, overview of the situation of R&D and access to medicines;
  Chapter 2: Mapping of current activities related to R&D and access to medicines;
  Chapter 3: Lessons learnt and implementation of the recommendations of the GSPA evaluation report.
- Sub-group calls held to monitor drafting of chapters & to ensure involvement of group members
- Chapters 1 & 3 drafted and commissioning of research work for Chapter 2
- On-line survey questionnaire developed to consult with Member States and stakeholders from private sector, inter and non-governmental organizations, academics etc. on the relevance of the GSPA-PHI elements and sub-elements & way forward.
Objectives of the second experts panel meeting
14 & 15 June

• Presentation and review of Chapter 1 and 3 and of data for Chapter 2 in plenary and in group work
• Identify gaps and additional work and research needed
• Review of Member States and stakeholders surveys results
• Develop outline for the final chapter (the way forward and implementation plan)
• Timelines and objectives of next meeting and expected deliverables
Next Steps and Timelines

• Drafting of the final chapter (June - July)
• Finalize all chapters and transmission of draft report to the experts panel for comments (first week of September)
• Editing of report (1st week of September)
• Third and final meeting, endorsement of report by panel, (14-15 September)
• Submission of report to DG and to translation (2 October)
• The final report will be presented to the Seventy-first World Health Assembly in 2018 (May 2018) through the Executive Board at its 142nd session (January 2018).
Questions for the open session

• In the context of the GSPA-PHI, how can R&D for medicines be improved? (please feel free to comment on any aspect of R&D for medicines, from issues relating to intellectual property to possible funding models)

• In the context of the GSPA-PHI, how can access to medicines be improved?

• Are there any issues not addressed by the GSPA-PHI and that you consider relevant to R&D and access to medicines? Are there elements, sub-elements or actions that you would drop?